Immunotherapies targeting CD38 in Multiple Myeloma

Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerabi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Atanackovic, Djordje, Steinbach, Mary, Radhakrishnan, Sabarinath Venniyil, Luetkens, Tim
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5139636/
https://ncbi.nlm.nih.gov/pubmed/27999737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1217374
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky